Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients

Akira Hirasawa, Takeru Zama, Tomoko Akahane, Hiroyuki Nomura, Fumio Kataoka, Koichiro Saito, Keisuke Okubo, Eiichiro Tominaga, Kazuya Makita, Nobuyuki Susumu, Kenjiro Kosaki, Yusuke Tanigawara, Daisuke Aoki

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Irinotecan is a key chemotherapeutic drug used to treat many tumors, including cervical and ovarian cancers; however, irinotecan can cause toxicity, particularly in the presence of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene polymorphisms, which are associated with reduced enzyme activity. Here, we investigated the prevalence of three different variants of UGT1A1 (UGT1A1*6, UGT1A1*27 and UGT1A1*28) and their relationships with irinotecan-induced adverse events in patients with gynecologic cancer, who are treated with lower doses of irinotecan than patients with other types of solid tumors. Fifty-three female patients treated with irinotecan and 362 female patients not treated with irinotecan were screened for UGT1A1*6, UGT1A1*27 and UGT1A1*28. Homozygosity for UGT1A1*6 or heterozygosity for UGT1A1*6/*28 was associated with a high risk of severe absolute neutrophil count decrease or diarrhea (odds ratios: 16.03 and 31.33, respectively). In contrast, serum bilirubin levels were not associated with irinotecan toxicity. Homozygosity for UGT1A1*6/*6 and heterozygosity for UGT1A1*6/*28 were associated with an increased risk of absolute neutrophil count and/or diarrhea in Japanese gynecologic cancer patients, despite the lower doses of irinotecan used in these patients. UGT1A1*6 and UGT1A1*28 are potential predictors of severe absolute neutrophil decrease and diarrhea caused by low-dose irinotecan in gynecologic cancer patients.

Original languageEnglish
Pages (from-to)794-798
Number of pages5
JournalJournal of Human Genetics
Volume58
Issue number12
DOIs
Publication statusPublished - Dec 1 2013
Externally publishedYes

Fingerprint

irinotecan
Glucuronosyltransferase
Uridine Diphosphate
Genes
Neoplasms
Therapeutics
Diarrhea
Neutrophils

Keywords

  • Gynecologic cancer
  • Hyperbilirubinemia
  • Irinotecan
  • Pharmacogenomics
  • Polymorphism
  • UGT1A1

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients. / Hirasawa, Akira; Zama, Takeru; Akahane, Tomoko; Nomura, Hiroyuki; Kataoka, Fumio; Saito, Koichiro; Okubo, Keisuke; Tominaga, Eiichiro; Makita, Kazuya; Susumu, Nobuyuki; Kosaki, Kenjiro; Tanigawara, Yusuke; Aoki, Daisuke.

In: Journal of Human Genetics, Vol. 58, No. 12, 01.12.2013, p. 794-798.

Research output: Contribution to journalArticle

Hirasawa, A, Zama, T, Akahane, T, Nomura, H, Kataoka, F, Saito, K, Okubo, K, Tominaga, E, Makita, K, Susumu, N, Kosaki, K, Tanigawara, Y & Aoki, D 2013, 'Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients', Journal of Human Genetics, vol. 58, no. 12, pp. 794-798. https://doi.org/10.1038/jhg.2013.105
Hirasawa, Akira ; Zama, Takeru ; Akahane, Tomoko ; Nomura, Hiroyuki ; Kataoka, Fumio ; Saito, Koichiro ; Okubo, Keisuke ; Tominaga, Eiichiro ; Makita, Kazuya ; Susumu, Nobuyuki ; Kosaki, Kenjiro ; Tanigawara, Yusuke ; Aoki, Daisuke. / Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients. In: Journal of Human Genetics. 2013 ; Vol. 58, No. 12. pp. 794-798.
@article{87f4f48677e142baa63bd7822d2eee3d,
title = "Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients",
abstract = "Irinotecan is a key chemotherapeutic drug used to treat many tumors, including cervical and ovarian cancers; however, irinotecan can cause toxicity, particularly in the presence of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene polymorphisms, which are associated with reduced enzyme activity. Here, we investigated the prevalence of three different variants of UGT1A1 (UGT1A1*6, UGT1A1*27 and UGT1A1*28) and their relationships with irinotecan-induced adverse events in patients with gynecologic cancer, who are treated with lower doses of irinotecan than patients with other types of solid tumors. Fifty-three female patients treated with irinotecan and 362 female patients not treated with irinotecan were screened for UGT1A1*6, UGT1A1*27 and UGT1A1*28. Homozygosity for UGT1A1*6 or heterozygosity for UGT1A1*6/*28 was associated with a high risk of severe absolute neutrophil count decrease or diarrhea (odds ratios: 16.03 and 31.33, respectively). In contrast, serum bilirubin levels were not associated with irinotecan toxicity. Homozygosity for UGT1A1*6/*6 and heterozygosity for UGT1A1*6/*28 were associated with an increased risk of absolute neutrophil count and/or diarrhea in Japanese gynecologic cancer patients, despite the lower doses of irinotecan used in these patients. UGT1A1*6 and UGT1A1*28 are potential predictors of severe absolute neutrophil decrease and diarrhea caused by low-dose irinotecan in gynecologic cancer patients.",
keywords = "Gynecologic cancer, Hyperbilirubinemia, Irinotecan, Pharmacogenomics, Polymorphism, UGT1A1",
author = "Akira Hirasawa and Takeru Zama and Tomoko Akahane and Hiroyuki Nomura and Fumio Kataoka and Koichiro Saito and Keisuke Okubo and Eiichiro Tominaga and Kazuya Makita and Nobuyuki Susumu and Kenjiro Kosaki and Yusuke Tanigawara and Daisuke Aoki",
year = "2013",
month = "12",
day = "1",
doi = "10.1038/jhg.2013.105",
language = "English",
volume = "58",
pages = "794--798",
journal = "Journal of Human Genetics",
issn = "1434-5161",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients

AU - Hirasawa, Akira

AU - Zama, Takeru

AU - Akahane, Tomoko

AU - Nomura, Hiroyuki

AU - Kataoka, Fumio

AU - Saito, Koichiro

AU - Okubo, Keisuke

AU - Tominaga, Eiichiro

AU - Makita, Kazuya

AU - Susumu, Nobuyuki

AU - Kosaki, Kenjiro

AU - Tanigawara, Yusuke

AU - Aoki, Daisuke

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Irinotecan is a key chemotherapeutic drug used to treat many tumors, including cervical and ovarian cancers; however, irinotecan can cause toxicity, particularly in the presence of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene polymorphisms, which are associated with reduced enzyme activity. Here, we investigated the prevalence of three different variants of UGT1A1 (UGT1A1*6, UGT1A1*27 and UGT1A1*28) and their relationships with irinotecan-induced adverse events in patients with gynecologic cancer, who are treated with lower doses of irinotecan than patients with other types of solid tumors. Fifty-three female patients treated with irinotecan and 362 female patients not treated with irinotecan were screened for UGT1A1*6, UGT1A1*27 and UGT1A1*28. Homozygosity for UGT1A1*6 or heterozygosity for UGT1A1*6/*28 was associated with a high risk of severe absolute neutrophil count decrease or diarrhea (odds ratios: 16.03 and 31.33, respectively). In contrast, serum bilirubin levels were not associated with irinotecan toxicity. Homozygosity for UGT1A1*6/*6 and heterozygosity for UGT1A1*6/*28 were associated with an increased risk of absolute neutrophil count and/or diarrhea in Japanese gynecologic cancer patients, despite the lower doses of irinotecan used in these patients. UGT1A1*6 and UGT1A1*28 are potential predictors of severe absolute neutrophil decrease and diarrhea caused by low-dose irinotecan in gynecologic cancer patients.

AB - Irinotecan is a key chemotherapeutic drug used to treat many tumors, including cervical and ovarian cancers; however, irinotecan can cause toxicity, particularly in the presence of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene polymorphisms, which are associated with reduced enzyme activity. Here, we investigated the prevalence of three different variants of UGT1A1 (UGT1A1*6, UGT1A1*27 and UGT1A1*28) and their relationships with irinotecan-induced adverse events in patients with gynecologic cancer, who are treated with lower doses of irinotecan than patients with other types of solid tumors. Fifty-three female patients treated with irinotecan and 362 female patients not treated with irinotecan were screened for UGT1A1*6, UGT1A1*27 and UGT1A1*28. Homozygosity for UGT1A1*6 or heterozygosity for UGT1A1*6/*28 was associated with a high risk of severe absolute neutrophil count decrease or diarrhea (odds ratios: 16.03 and 31.33, respectively). In contrast, serum bilirubin levels were not associated with irinotecan toxicity. Homozygosity for UGT1A1*6/*6 and heterozygosity for UGT1A1*6/*28 were associated with an increased risk of absolute neutrophil count and/or diarrhea in Japanese gynecologic cancer patients, despite the lower doses of irinotecan used in these patients. UGT1A1*6 and UGT1A1*28 are potential predictors of severe absolute neutrophil decrease and diarrhea caused by low-dose irinotecan in gynecologic cancer patients.

KW - Gynecologic cancer

KW - Hyperbilirubinemia

KW - Irinotecan

KW - Pharmacogenomics

KW - Polymorphism

KW - UGT1A1

UR - http://www.scopus.com/inward/record.url?scp=84890959906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890959906&partnerID=8YFLogxK

U2 - 10.1038/jhg.2013.105

DO - 10.1038/jhg.2013.105

M3 - Article

C2 - 24088669

AN - SCOPUS:84890959906

VL - 58

SP - 794

EP - 798

JO - Journal of Human Genetics

JF - Journal of Human Genetics

SN - 1434-5161

IS - 12

ER -